JP5570429B2 - デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 - Google Patents

デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 Download PDF

Info

Publication number
JP5570429B2
JP5570429B2 JP2010535152A JP2010535152A JP5570429B2 JP 5570429 B2 JP5570429 B2 JP 5570429B2 JP 2010535152 A JP2010535152 A JP 2010535152A JP 2010535152 A JP2010535152 A JP 2010535152A JP 5570429 B2 JP5570429 B2 JP 5570429B2
Authority
JP
Japan
Prior art keywords
patient
administered
antitumor agent
cyano
pyrimidinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010535152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518761A (ja
JP2011518761A5 (enExample
Inventor
博之 岡部
和人 荒川
Original Assignee
Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 filed Critical Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社
Publication of JP2011518761A publication Critical patent/JP2011518761A/ja
Publication of JP2011518761A5 publication Critical patent/JP2011518761A5/ja
Application granted granted Critical
Publication of JP5570429B2 publication Critical patent/JP5570429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010535152A 2008-04-29 2009-04-28 デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 Active JP5570429B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/111,369 2008-04-29
US12/111,369 US7863255B2 (en) 2008-04-29 2008-04-29 Methods of administering antitumor agent comprising deoxycytidine derivative
PCT/JP2009/058725 WO2009133963A1 (en) 2008-04-29 2009-04-28 Methods of administering antitumor agent comprising deoxycytidine derivative

Publications (3)

Publication Number Publication Date
JP2011518761A JP2011518761A (ja) 2011-06-30
JP2011518761A5 JP2011518761A5 (enExample) 2012-01-26
JP5570429B2 true JP5570429B2 (ja) 2014-08-13

Family

ID=41050984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535152A Active JP5570429B2 (ja) 2008-04-29 2009-04-28 デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法

Country Status (8)

Country Link
US (1) US7863255B2 (enExample)
EP (1) EP2268287B1 (enExample)
JP (1) JP5570429B2 (enExample)
AU (1) AU2009240908B2 (enExample)
DK (1) DK2268287T3 (enExample)
ES (1) ES2467968T3 (enExample)
PL (1) PL2268287T3 (enExample)
WO (1) WO2009133963A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022014025A1 (ja) 2020-07-17 2022-01-20 Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ株式会社 血液がんの新規治療法及び新規治療剤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP2014001204A (ja) * 2012-05-23 2014-01-09 Kumamoto Univ 腫瘍細胞選択的抗がん剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
GB0609530D0 (en) * 2006-05-12 2006-06-21 Cyclacel Ltd Combination

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022014025A1 (ja) 2020-07-17 2022-01-20 Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ株式会社 血液がんの新規治療法及び新規治療剤
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer

Also Published As

Publication number Publication date
AU2009240908A1 (en) 2009-11-05
PL2268287T3 (pl) 2014-10-31
DK2268287T3 (da) 2014-06-02
US20090270340A1 (en) 2009-10-29
US7863255B2 (en) 2011-01-04
AU2009240908B2 (en) 2013-10-03
JP2011518761A (ja) 2011-06-30
ES2467968T3 (es) 2014-06-13
EP2268287B1 (en) 2014-05-21
WO2009133963A1 (en) 2009-11-05
EP2268287A1 (en) 2011-01-05

Similar Documents

Publication Publication Date Title
ES2705016T3 (es) Derivado de rapamicina para el tratamiento de cáncer de pulmón
EP3449919B1 (en) Method for treating pleuroperitoneal membrane cancers by locally injecting disulfiram preparation
KR20210068344A (ko) 고시폴, 펜포르민 및 항암제를 포함하는 암 예방 또는 치료용 약학적 조성물
JP5570429B2 (ja) デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
WO1992011247A1 (fr) Composition anticancereuse et compose
JP5066737B2 (ja) シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
ES2317913T3 (es) Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito.
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
JP5581200B2 (ja) シチジン誘導体及びカルボプラチンを含有する抗腫瘍剤
KR20080000628A (ko) 방사선 치료 증강제
JP2021533112A (ja) 癌を治療するための併用療法
TW202000207A (zh) 膀胱癌用抗腫瘤劑及膀胱癌的處置方法
JPS6337767B2 (enExample)
EP2431032A1 (en) Anti-tumor agent comprising tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
WO2025162314A1 (zh) 包含prmt5抑制剂和pd-1/pd-l1抑制剂的药物组合物
WO2022014025A1 (ja) 血液がんの新規治療法及び新規治療剤
TW202203942A (zh) 血液癌之新穎治療法及新穎治療劑
HK1150151A (en) Anti-tumor agent comprising cytidine derivative and carboplatin
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110328

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140624

R150 Certificate of patent or registration of utility model

Ref document number: 5570429

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100917

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250